DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder

被引:23
|
作者
Burghardt, Kyle J. [1 ]
Goodrich, Jacyln M. [2 ]
Dolinoy, Dana C. [2 ]
Ellingrod, Vicki L. [3 ,4 ]
机构
[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharm Practice, Detroit, MI 48201 USA
[2] Univ Michigan, Sch Publ Hlth, Dept Environm Sci, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Clin Social & Adm Sci, Coll Pharm, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA
关键词
antipsychotic; bipolar; global DNA methylation; insulin resistance; REDUCTASE MTHFR 677C/T; METABOLIC SYNDROME; LUMINOMETRIC METHYLATION; GENE-EXPRESSION; RISK-FACTORS; SCHIZOPHRENIA; ASSOCIATION; OBESITY; ASSAY; METAANALYSIS;
D O I
10.2217/epi.15.5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Aims: This study aimed to assess the effect of second-generation antipsychotic (SGA) use and insulin resistance on a global measure of DNA methylation in patients diagnosed with bipolar disorder. Materials & Methods: Subjects stable on medication (either mood stabilizer monotherapy or adjuvant SGAs) were assessed for insulin resistance. Global methylation levels were assessed in leukocyte DNA from whole blood using the Luminometric Methylation Assay. Multivariable linear regression was used to investigate the effect of insulin resistance and SGA use on DNA methylation. Results: A total of 115 bipolar I subjects were included in this study. The average age was 43.1 +/- 12.2 years and 73% were on SGAs. Average% global methylation was 77.0 +/- 3.26 and was significantly influenced by insulin resistance, SGA use and smoking. Conclusion: This is the first study to show a relationship between SGA use, insulin resistance and global DNA methylation. Further work will be needed to identify tissue- and gene-specific methylation changes.
引用
收藏
页码:343 / 352
页数:10
相关论文
共 50 条
  • [31] Second-generation antipsychotics for anxiety disorders
    Depping, Anna M.
    Komossa, Katja
    Kissling, Werner
    Leucht, Stefan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):
  • [32] Second-Generation Antipsychotics and VTE Risk
    Deloughery, Emma P.
    BLOOD, 2023, 142
  • [33] Second-generation antipsychotics: a therapeutic downturn?
    Lewis, Shon
    PSYCHOLOGICAL MEDICINE, 2009, 39 (10) : 1603 - 1606
  • [34] Tardive dyskinesia and second-generation antipsychotics
    Ross, DE
    AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (02): : 405 - 405
  • [35] Second-generation antipsychotics - Aripiprazole revisited
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1219): : 81 - 82
  • [37] Second-Generation Antipsychotics and Suicide: A Commentary
    Zuschlag, Zachary D.
    JOURNAL OF CLINICAL PSYCHIATRY, 2021, 82 (05)
  • [38] Assessing the Costs of Second-Generation Antipsychotics
    Pfeiffer, Paul N.
    Valenstein, Marcia
    PSYCHIATRIC SERVICES, 2012, 63 (03) : 199 - 199
  • [39] Second-generation antipsychotics and pregnancy complications
    Maria Ellfolk
    Maarit K. Leinonen
    Mika Gissler
    Anna-Maria Lahesmaa-Korpinen
    Leena Saastamoinen
    Marja-Leena Nurminen
    Heli Malm
    European Journal of Clinical Pharmacology, 2020, 76 : 107 - 115
  • [40] Diabetes and second-generation (atypical) antipsychotics
    Chabroux, S.
    Haffen, E.
    Penfornis, A.
    ANNALES D ENDOCRINOLOGIE, 2009, 70 (04) : 202 - 210